Metabolic Research in Schizophrenia Laboratory 
 |
 |
 |
 |
 |
 |
| Publications |
|
1. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacology, 2001; 21(4): 369-74. 2. Meyer JM. Individual alterations in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacology, 2001; 21(6): 569-74. 3. Jin H. Meyer JM. Jeste DV. The phenomenology of new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry 2002; 14(1): 59-64. 4. Meyer JM. Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study. Annals of Clinical Psychiatry, March 2002; 14(1): 27-34. 5. Meyer JM. Metabolic outcomes after one year: a retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients. J Clin Psychiatry, May 2002; 63(5): 425-33. 6. Meyer JM. Prevalence of hepatitis A, hepatitis B and HIV among hepatitis C seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry 2003, 64(5): 540-45. 7. Loh C, Leckband S, Meyer JM, Turner E. Risperidone-induced retrograde ejaculation: case report and review of the literature. Intl Clinical Psychopharmacol 2004; 19:111-12. 8. Meyer JM, Leckband SG, Loh C, Moutier CY. Quetiapine-induced diabetes with metabolic acidosis: a case report. Intl Clinical Psychopharmacol 2004; 19:169-71. 9. Meyer JM, Koro CE. The Effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 2004; 70(1):1-17. 10. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 2004; 71(2-3):195-212. 11. Meyer JM. Treating the mind and body in schizophrenia: risks and prevention. CNS Spectrums 2004; 9(10 Suppl 11):25-33. 12. Kimmel RJ, Irwin SA, Meyer JM. Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Intl Clinical Psychopharmacol 2005; 20(1):57-8. 13. Lehman D, Meyer JM. Decreased bone mineral density in male schizophrenia patients. Schizophrenia Research 2005; 76(1):131-33 14. Meyer JM, Dollarhide A, Tuan I-L. Lithium toxicity after switch from fosinopril to lisinopril: a case report. Intl Clinical Psychopharmacol 2005; 20(2):115-18 15. Meyer JM, Koro CE, L’Italien GJ. The metabolic syndrome and schizophrenia: a review. Intl Review Psychiatry 2005; 17(3):173-80 16. Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 2005; 6(3): 148-57. 17. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Stroup TS, Lieberman JA. The CATIE Schizophrenia Trial: clinical comparison of subgroups with and without the Metabolic Syndrome. Schiz Research 2005; 80(1):9-18 18. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Sullivan L, Meltzer HY, Stroup TS, Lieberman JA. Prevalence of the Metabolic Syndrome in patients with schizophrenia: baseline results from CATIE and comparison with national estimates from NHANES III. Schiz Research 2005; 80(1):19-32 19. Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nasrallah HA, Daumit G, Lamberti S, D’Agnostino RB, Stroup TS, Lieberman JA.A Comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schiz Research 2005; 80(1):45-53 20. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Impact of an open-label switch from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder. Clinical Therapeutics 2005;27(12):1930-41 21. Meyer JM, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatric Practice 2006; 12(1):5-10. 22. Loh C, Meyer JM, Leckband S. A comprehensive review of behavioral interventions for weight management in schizophrenia. Annals of Clinical Psychiatry 2006; 18(1):23-31 23. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients. Annals of Clinical Psychiatry 2006; 18(1):43-48 |
|||
 |
 |
 |
 |
